A Prospective Single-Arm, Multi-Centre, Study of the Efficacy and Safety of Lutetium-177 Octreotate (Lu-DOTATATE) Treatment With Individualized Dosimetry in Patients With 68Ga-DOTATATE Identified Somatostatin Receptor Positive Neuroendocrine Tumours
This is a prospective single arm, multicentre study will evaluate the efficacy and safety of
Lutetium-177 Octreotate in patients with neuroendocrine tumours who has positive Somatostatin
receptor identified by 68Ga-DOTATATE. 195 patients will be enrolled totally. Patient who has
progressed with neuroendocrine tumour will be evaluated by the tumour board first and eligible
patients will undergo diagnostic Ga 68 PET scan. Patients who showed Somatostatin will
undergo 4 cycles of Lu-DOTATATE treatment. Dose adjustment for Cycle 2-4 will be made based
on individualized dosimetry, as well as creatinine clearance and hematological parameters.
Patients will be evaluated progression free survival at 12 months from last dose. Patients
who are negative for somatostatin will not receive 68Ga-DOTATATE treatment but will be
followed until progression and acts as control group.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society